Novavax: Will it recover from this?

Novavax: This is what the sentiment says

Novavax has not seen any significant change in the sentiment picture in recent weeks. A change in the sentiment picture occurs when the mass of market participants in the social media, which form the basis of this evaluation, have a tendency towards particularly positive or negative topics. Since no conspicuities were registered in this respect at Novavax, we rate this criterion as “Hold”. With regard to the strength of the discussion, or in other words, the change in the number of posts, no significant differences could be identified. We reward this with a “Hold” rating. In summary, Novavax therefore gets a “Hold” for this stage.

The bears have Novavax firmly in their grip

Comparing the moving average of the closing price of Novavax shares over the last 200 trading days (GD200) of $48.05 with the current price ($17.03), we find a deviation of -64.56 percent. This gives the stock a “Sell” rating from a chart perspective for the GD200. Let’s look at the moving average of the closing price of the last 50 trading days (GD50). For this ($20.95), the last closing price is also below the moving average (-18.71 percent deviation). Novavax shares are thus given a “sell” rating on this shorter-term basis as well. Overall, the company thus receives a “sell” rating for the simple chart technique.

What price signs does the RSI indicate?

With the help of the Relative Strength Index (RSI), an indicator from technical analysis, a statement can be made as to whether a security is “overbought” or “oversold”. For this purpose, the upward and downward movements of an underlying security over time are put into relation. Let’s take a look at the RSI of the last 7 days for the Novavax share. The value is currently 96.18. Accordingly, the security is overbought and we therefore assign a “sell” rating. The RSI of the last 25 trading days is less volatile than the RSI7 and complements our analysis with a longer-term view. In contrast to the RSI of the last 7 trading days, Novavax is neither overbought nor oversold on this basis. The thus divergent rating of the stock for the 25-day RSI is therefore a “hold” rating. Overall, the analysis of the RSIs on Novavax thus provides a “Sell” rating.

Analysts are positive

Novavax has received a total of 6 analyst ratings in the past twelve months.The average rating for the stock is “Buy” and is composed of 5 “Buy”, 1 “Hold” and 0 “Sell” opinions. There are no analyst updates on Novavax from the last month. Based on the average of the price forecast of ($190.17) for the security, there is a potential upside of 1016.66% (from the last closing price, $17.03), following the analysts’ opinion. This therefore represents a “buy” recommendation. Novavax thus receives a “Buy” rating for this section in total.